Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial

被引:46
作者
Evans, S
Newton, R
Higgins, S
机构
[1] Frankston Hosp, Dept Nutr & Dietet, Peninsula Hlth, Frankston, Vic 3199, Australia
[2] Monash Univ, Dept Psychol Med, Clayton, Vic 3168, Australia
[3] Frankston Hosp, Dept Psychiat, Frankston, Australia
关键词
antipsychotics; dietitian; nutrition; olanzapine; weight gain;
D O I
10.1080/j.1440-1614.2005.01607.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Olanzapine is the most commonly prescribed atypical antipsychotic medication in Australia. Research reports an average weight gain of between 4.5 and 7 kg in the 3 months following its commencement. Trying to minimize this weight gain in a population with an already high prevalence of obesity, mortality and morbidity is of clinical and social importance. This randomized controlled trial investigated the impact of individual nutrition education provided by a dietitian on weight gain in the 3 and 6 months following the commencement of olanzapine. Method: Fifty-one individuals (29 females, 22 males) who had started on olanzapine in the previous 3 months (mean length of 27 days +/- 20) were recruited through Peninsula Health Psychiatric Services and were randomly assigned to either the intervention (n = 29) or the control group (n = 22). Individuals in the intervention group received six 1 hour nutrition education sessions over a 3-month period. Weight, waist circumference, body mass index (BMI) and qualitative measures of exercise levels, quality of life, health and body image were collected at baseline at 3 and 6 months. Results: After 3 months, the control group had gained significantly more weight than the treatment group (6.0 kg vs 2.0 kg, p <= 0.002). Weight gain of more than 7% of initial weight occurred in 64% of the control group compared to 13% of the treatment group. The control group's BMI increased significantly more than the treatment group's (2 kg/m(2)vs 0.7 kg/m(2), p <= 0.03). The treatment group reported significantly greater improvements in moderate exercise levels, quality of life, health and body image compared to the controls. At 6 months, the control group continued to show significantly more weight gain since baseline than the treatment group (9.9 kg vs 2.0 kg, p <= 0.013) and consequently had significantly greater increases in BMI (3.2 kg/m(2)vs 0.8 kg/m(2), p <= 0.017). Conclusion: Individual nutritional intervention provided by a dietitian is highly successful at preventing olanzapine-induced weight gain.
引用
收藏
页码:479 / 486
页数:8
相关论文
共 37 条
[1]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[2]  
Allison DB, 2001, J CLIN PSYCHIAT, V62, P22
[3]   Orlistat in the treatment of psychopharmacologically induced weight gain [J].
Anghelescu, I ;
Klawe, C ;
Benkert, O .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (06) :716-717
[4]   Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics [J].
Atmaca, M ;
Kuloglu, M ;
Tezcan, E ;
Ustundag, B .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (05) :598-604
[5]   A program for treating olanzapine-related weight gain [J].
Ball, MP ;
Coons, VB ;
Buchanan, RW .
PSYCHIATRIC SERVICES, 2001, 52 (07) :967-969
[6]   Body weight gain induced by antipsychotic drugs: mechanisms and management [J].
Baptista, T .
ACTA PSYCHIATRICA SCANDINAVICA, 1999, 100 (01) :3-16
[7]  
BARHAM P, 1995, PSYCHOSIS UNDERSTAND, V1, P23
[8]  
Baruch R, 2002, SCHIZOPHR RES, V53, P159
[9]  
Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13
[10]  
Beasley CM, 1997, J CLIN PSYCHIAT, V58, P7